A detailed history of Farther Finance Advisors, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Farther Finance Advisors, LLC holds 2,754 shares of NBIX stock, worth $398,944. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,754
Previous 1,134 142.86%
Holding current value
$398,944
Previous $159 Million 145.37%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 23, 2026

BUY
$136.63 - $154.8 $221,340 - $250,776
1,620 Added 142.86%
2,754 $391 Million
Q3 2025

Oct 14, 2025

BUY
$123.98 - $146.67 $26,655 - $31,534
215 Added 23.39%
1,134 $159 Million
Q2 2025

Jul 11, 2025

BUY
$87.54 - $128.18 $20,396 - $29,865
233 Added 33.97%
919 $116 Million
Q1 2025

Apr 14, 2025

BUY
$107.22 - $153.29 $20,693 - $29,584
193 Added 39.15%
686 $73.4 Million
Q4 2024

Feb 07, 2025

BUY
$111.62 - $139.44 $5,692 - $7,111
51 Added 11.54%
493 $67.3 Million
Q2 2024

Jul 31, 2024

BUY
$130.86 - $143.19 $916 - $1,002
7 Added 1.61%
442 $61.9 Million
Q1 2024

May 13, 2024

BUY
$130.4 - $143.74 $55,420 - $61,089
425 Added 4250.0%
435 $61.5 Million
Q4 2023

Feb 14, 2024

BUY
$106.07 - $132.76 $742 - $929
7 Added 1.65%
430 $56.7 Million
Q3 2023

Nov 13, 2023

BUY
$94.02 - $117.1 $38,830 - $48,362
413 Added 4130.0%
423 $47.6 Million
Q2 2023

May 13, 2024

BUY
$89.53 - $104.87 $447 - $524
5 Added 100.0%
10 $943,000
Q2 2023

Sep 12, 2023

BUY
$89.53 - $104.87 $447 - $524
5 Added 100.0%
10 $943,000
Q1 2023

May 13, 2024

SELL
$94.11 - $123.02 $39,996 - $52,283
-425 Reduced 98.84%
5 $506,000
Q4 2022

Sep 11, 2023

BUY
$106.72 - $127.06 $533 - $635
5 New
5 $597,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.9B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Farther Finance Advisors, LLC Portfolio

Follow Farther Finance Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farther Finance Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farther Finance Advisors, LLC with notifications on news.